KM-233: Difference between revisions
CSV import |
CSV import |
||
| Line 33: | Line 33: | ||
{{Psychoactive drug-stub}} | {{Psychoactive drug-stub}} | ||
{{Cannabinoid-stub}} | {{Cannabinoid-stub}} | ||
{{No image}} | |||
Revision as of 20:46, 10 February 2025
KM-233 is a synthetic compound that exhibits psychoactive properties. It is a derivative of cannabinoid, a class of chemicals that interact with the endocannabinoid system in the human body. KM-233 was developed in the early 21st century and has been the subject of ongoing research due to its potential therapeutic applications.
History
KM-233 was first synthesized in the early 2000s by a team of researchers led by Dr. Alexandros Makriyannis at the Northeastern University. The compound was developed as part of a broader effort to create synthetic cannabinoids that could be used in medical treatments.
Chemistry
KM-233 is a derivative of the cannabinoid class of chemicals. It is a complex molecule that is synthesized through a multi-step process. The compound is characterized by its unique structure, which includes a phenyl group and a naphthoyl group. These structural elements are believed to contribute to the compound's psychoactive properties.
Pharmacology
KM-233 interacts with the endocannabinoid system in the human body. This system is composed of cannabinoid receptors, which are found in various tissues throughout the body. KM-233 is believed to bind to these receptors, triggering a range of physiological responses.
The exact mechanism of action of KM-233 is not fully understood. However, it is known that the compound has a high affinity for the CB1 receptor, one of the two main types of cannabinoid receptors. This suggests that KM-233 may exert its effects primarily through interactions with this receptor.
Potential Therapeutic Applications
Research into the potential therapeutic applications of KM-233 is ongoing. The compound's ability to interact with the endocannabinoid system suggests that it may have potential uses in the treatment of a range of conditions, including chronic pain, inflammation, and certain neurological disorders.
However, much more research is needed to fully understand the potential benefits and risks of KM-233. As of now, the compound is not approved for use in any medical treatments.
See Also
This article is a Psychoactive drug-related stub. You can help WikiMD by expanding it!
This article is a cannabinoid related stub. You can help WikiMD by expanding it!
